Search research articles
Contact Us
Filters
Showing results (121-130 of 143) with videos related to
Page
of 15
Sort By:
Cell Stem Cell
|
October 20, 2023
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation
Chun-Wei Chen, Linda Zhang, Ravi Dutta, et al.
Cell Stem Cell
|
February 2, 2024
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation
Chun-Wei Chen, Linda Zhang, Ravi Dutta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2024
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer
Stefania Morganti, Christopher J Gibson, Qingchun Jin, et al.
Journal of Geriatric Oncology
|
September 26, 2022
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer
Rachel A Freedman, Tianyu Li, Mina S Sedrak, et al.
Blood
|
May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Adam S Sperling, Michael Burgess, Hasmik Keshishian, et al.
Cancer Research
|
March 31, 2025
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect
Nancy Klemm, Roman R Schimmer, Nils K Konrad, et al.
Blood
|
September 12, 2022
Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19
Peter G Miller, Geoffrey G Fell, Brody H Foy, et al.
Blood
|
August 18, 2023
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
Peter G Miller, Adam S Sperling, Christina Mayerhofer, et al.
Science (New York, N.Y.)
|
August 10, 2019
A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies
Steffen Boettcher, Peter G Miller, Rohan Sharma, et al.
Blood
|
June 17, 2022
TET2-mutant clonal hematopoiesis and risk of gout
Mridul Agrawal, Abhishek Niroula, Pierre Cunin, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 143) with videos related to
Sort By:
Page
of 15
Cell Stem Cell
|
October 20, 2023
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation
Chun-Wei Chen, Linda Zhang, Ravi Dutta, et al.
Cell Stem Cell
|
February 2, 2024
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation
Chun-Wei Chen, Linda Zhang, Ravi Dutta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2024
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer
Stefania Morganti, Christopher J Gibson, Qingchun Jin, et al.
Journal of Geriatric Oncology
|
September 26, 2022
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer
Rachel A Freedman, Tianyu Li, Mina S Sedrak, et al.
Blood
|
May 3, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
Adam S Sperling, Michael Burgess, Hasmik Keshishian, et al.
Cancer Research
|
March 31, 2025
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect
Nancy Klemm, Roman R Schimmer, Nils K Konrad, et al.
Blood
|
September 12, 2022
Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19
Peter G Miller, Geoffrey G Fell, Brody H Foy, et al.
Blood
|
August 18, 2023
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
Peter G Miller, Adam S Sperling, Christina Mayerhofer, et al.
Science (New York, N.Y.)
|
August 10, 2019
A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies
Steffen Boettcher, Peter G Miller, Rohan Sharma, et al.
Blood
|
June 17, 2022
TET2-mutant clonal hematopoiesis and risk of gout
Mridul Agrawal, Abhishek Niroula, Pierre Cunin, et al.
Page
of 15